Intercept Pharmaceuticals Now Covered by Cowen and Company (ICPT)
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski unloaded 10,000 shares of Intercept Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $286.49, for a total value of $2,864,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Intercept Pharmaceuticals in a research note on Friday, August 15th. They set an “underperform” rating and a $172.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday, August 14th. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday, August 12th. They now have a $456.00 price target on the stock, up previously from $323.00. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $472.91.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 286.70 on Friday. Intercept Pharmaceuticals has a 52-week low of $45.55 and a 52-week high of $497.00. The stock has a 50-day moving average of $257.1 and a 200-day moving average of $288.1. The company’s market cap is $6.083 billion. Intercept Pharmaceuticals also saw a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 595,961 shares, a decline of 25.1% from the July 31st total of 795,445 shares. Based on an average trading volume of 1,067,623 shares, the days-to-cover ratio is currently 0.6 days. Approximately 4.2% of the company’s stock are sold short.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.79) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.34 EPS for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.